These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 25118597

  • 1. Sclerostin blood levels before and after kidney transplantation.
    Bonani M, Rodriguez D, Fehr T, Mohebbi N, Brockmann J, Blum M, Graf N, Frey D, Wüthrich RP.
    Kidney Blood Press Res; 2014; 39(4):230-9. PubMed ID: 25118597
    [Abstract] [Full Text] [Related]

  • 2. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.
    Voskaridou E, Christoulas D, Plata E, Bratengeier C, Anastasilakis AD, Komninaka V, Kaliontzi D, Gkotzamanidou M, Polyzos SA, Dimopoulou M, Terpos E.
    Horm Metab Res; 2012 Nov; 44(12):909-13. PubMed ID: 22581647
    [Abstract] [Full Text] [Related]

  • 3. Decreased Circulating Sclerostin Levels in Renal Transplant Recipients With Persistent Hyperparathyroidism.
    Evenepoel P, Claes K, Viaene L, Bammens B, Meijers B, Naesens M, Sprangers B, Kuypers D.
    Transplantation; 2016 Oct; 100(10):2188-93. PubMed ID: 27379556
    [Abstract] [Full Text] [Related]

  • 4. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults.
    Amrein K, Amrein S, Drexler C, Dimai HP, Dobnig H, Pfeifer K, Tomaschitz A, Pieber TR, Fahrleitner-Pammer A.
    J Clin Endocrinol Metab; 2012 Jan; 97(1):148-54. PubMed ID: 21994959
    [Abstract] [Full Text] [Related]

  • 5. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients.
    Ishimura E, Okuno S, Ichii M, Norimine K, Yamakawa T, Shoji S, Nishizawa Y, Inaba M.
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4315-20. PubMed ID: 25093620
    [Abstract] [Full Text] [Related]

  • 6. Sclerostin declines during hemodialysis and appears in Dialysate.
    Bielesz BO, Hempfing T, Kieweg H, Marculescu R, Haas M, Cejka D.
    Blood Purif; 2014 Nov; 38(1):30-6. PubMed ID: 25228355
    [Abstract] [Full Text] [Related]

  • 7. Renal elimination of sclerostin increases with declining kidney function.
    Cejka D, Marculescu R, Kozakowski N, Plischke M, Reiter T, Gessl A, Haas M.
    J Clin Endocrinol Metab; 2014 Jan; 99(1):248-55. PubMed ID: 24187403
    [Abstract] [Full Text] [Related]

  • 8. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
    Yamada S, Tsuruya K, Tokumoto M, Yoshida H, Ooboshi H, Kitazono T.
    Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190
    [Abstract] [Full Text] [Related]

  • 9. Sclerostin Serum Levels and Vascular Calcification Progression in Prevalent Renal Transplant Recipients.
    Evenepoel P, Goffin E, Meijers B, Kanaan N, Bammens B, Coche E, Claes K, Jadoul M.
    J Clin Endocrinol Metab; 2015 Dec; 100(12):4669-76. PubMed ID: 26505822
    [Abstract] [Full Text] [Related]

  • 10. Serum sclerostin levels associated with lumbar spine bone mineral density and bone turnover markers in patients with postmenopausal osteoporosis.
    Xu XJ, Shen L, Yang YP, Lu FR, Zhu R, Shuai B, Li CG, Wu MX.
    Chin Med J (Engl); 2013 Jul; 126(13):2480-4. PubMed ID: 23823821
    [Abstract] [Full Text] [Related]

  • 11. Relationship Between Osteoporosis and Serum Sclerostin Levels in Kidney Transplant Recipients.
    Basir H, Altunoren O, Erken E, Kilinc M, Sarisik FN, Isiktas S, Gungor O.
    Exp Clin Transplant; 2024 Jul; 22(7):514-521. PubMed ID: 31526333
    [Abstract] [Full Text] [Related]

  • 12. Two-year cortical and trabecular bone loss in CKD-5D: biochemical and clinical predictors.
    Malluche HH, Monier-Faugere MC, Blomquist G, Davenport DL.
    Osteoporos Int; 2018 Jan; 29(1):125-134. PubMed ID: 28993865
    [Abstract] [Full Text] [Related]

  • 13. Serum sclerostin in alcoholics: a pilot study.
    González-Reimers E, Martín-González C, de la Vega-Prieto MJ, Pelazas-González R, Fernández-Rodríguez C, López-Prieto J, Alvisa-Negrín J, Santolaria-Fernández F.
    Alcohol Alcohol; 2013 Jan; 48(3):278-82. PubMed ID: 23296214
    [Abstract] [Full Text] [Related]

  • 14. Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients.
    Kanbay M, Siriopol D, Saglam M, Kurt YG, Gok M, Cetinkaya H, Karaman M, Unal HU, Oguz Y, Sari S, Eyileten T, Goldsmith D, Vural A, Veisa G, Covic A, Yilmaz MI.
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E1854-61. PubMed ID: 25057883
    [Abstract] [Full Text] [Related]

  • 15. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients.
    Cejka D, Jäger-Lansky A, Kieweg H, Weber M, Bieglmayer C, Haider DG, Diarra D, Patsch JM, Kainberger F, Bohle B, Haas M.
    Nephrol Dial Transplant; 2012 Jan; 27(1):226-30. PubMed ID: 21613383
    [Abstract] [Full Text] [Related]

  • 16. Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus.
    Gaudio A, Privitera F, Battaglia K, Torrisi V, Sidoti MH, Pulvirenti I, Canzonieri E, Tringali G, Fiore CE.
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3744-50. PubMed ID: 22855334
    [Abstract] [Full Text] [Related]

  • 17. Sclerostin, Osteocytes, and Chronic Kidney Disease - Mineral Bone Disorder.
    Moysés RM, Schiavi SC.
    Semin Dial; 2015 Oct; 28(6):578-86. PubMed ID: 26288182
    [Abstract] [Full Text] [Related]

  • 18. Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis?
    Viaene L, Behets GJ, Claes K, Meijers B, Blocki F, Brandenburg V, Evenepoel P, D'Haese PC.
    Nephrol Dial Transplant; 2013 Dec; 28(12):3024-30. PubMed ID: 23605174
    [Abstract] [Full Text] [Related]

  • 19. Sclerostin and Dickkopf-1 in post-menopausal renal allograft recipients.
    Tomei P, Zaza G, Granata S, Gatti D, Fraccarollo C, Gesualdo L, Boschiero L, Lupo A.
    Transplant Proc; 2014 Sep; 46(7):2241-6. PubMed ID: 25242761
    [Abstract] [Full Text] [Related]

  • 20. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
    Gatti D, Viapiana O, Fracassi E, Idolazzi L, Dartizio C, Povino MR, Adami S, Rossini M.
    J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.